- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Steglatro formulary decision guide intended for HCPs was visible through transparent wrappers used for some mailed journals. MSD admitted a breach…
A patient complained about a YouTube-hosted meeting recording mentioning Lixiana. Most allegations were not upheld, but Daiichi-Sankyo was found in breach for…
A national newspaper osteoporosis awareness ad “supported by Amgen” was not POM promotion, but was ruled misleading for implying patients could get…
Anonymous employee alleged poor diabetes rep training and over-reliance on a fellow representative. Panel found complaint unproven on balance of probabilities; no…
Anonymous ex-employee alleged Lecigon advisory boards were marketing-led/disguised promotion and that a nursing service was compromised by sales access to patient data.…
A Skyrizi banner on a nursing group website claimed “BAD Guidelines recommend Skyrizi as a first line biologic”. PMCPA ruled it misleading…
A draft “footer content” webpage became searchable on Daiichi-Sankyo’s UK site and promoted olmesartan, prasugrel and edoxaban to the public without PI…
Britannia was found in breach for paying unwarranted HCP preparation time (not FMV), making payments without fully executed contracts, and failing to…
Otsuka Europe and Otsuka UK voluntarily admitted Abilify Maintena prescribing information omitted the word “monthly” for IM maintenance dosing. The error persisted…
Lundbeck was found in breach after Vyepti (eptinezumab) was promoted before UK marketing authorisation at a Migraine Trust virtual symposium and via…
A webinar invite sent via an independent organisation looked like the organisation’s own event. PMCPA found Novo Nordisk’s “organised and fully funded”…
A MIMS Live event reminder offered a prize draw requiring attendance across all days, including Chiesi’s promotional session. The email didn’t clearly…
A UK-based contractor posted about oral semaglutide and linked a media article on LinkedIn. The Panel said the post was promotional and…
Two Lixiana patient booklets were ruled misleading for omitting PIL-listed signs of excessive bleeding and implying they contained all relevant safety info.…
Health professional alleged Roche needed separate certification for mobile webpage and that a meeting title implied broader HER2+ eBC indications for Kadcyla/Perjeta.…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.